|
gptkbp:instance_of
|
gptkb:vaccine
|
|
gptkbp:accessories
|
multiple countries
|
|
gptkbp:adjuvant
|
gptkb:Matrix-M
|
|
gptkbp:average_temperature
|
2 to 8 degrees Celsius
|
|
gptkbp:clinical_trial
|
over 30,000
multiple countries
Phase 3
|
|
gptkbp:clinical_trial_results_published
|
gptkb:2021
|
|
gptkbp:developed_by
|
Novavax, Inc.
|
|
gptkbp:dosage_form
|
recommended after initial series
two doses
|
|
gptkbp:emergency_services
|
gptkb:United_States
|
|
gptkbp:first_doses_administered
|
gptkb:2021
|
|
gptkbp:funding
|
government grants
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Novavax's COVID-19 vaccine
|
|
gptkbp:is_effective_against
|
approximately 90% in clinical trials
|
|
gptkbp:is_vulnerable_to
|
gptkb:Bill_&_Melinda_Gates_Foundation
gptkb:NIAID
gptkb:CEPI
gptkb:2021
global
ongoing
against variants
subunit vaccine
contributing to herd immunity
reducing hospitalizations
reducing severe cases
standard refrigeration
against hospitalization
against symptomatic infection
recombinant technology
against death
Nuvaxovid
|
|
gptkbp:manufacturer
|
Novavax, Inc.
|
|
gptkbp:partnerships
|
various governments
|
|
gptkbp:regulatory_compliance
|
gptkb:various_countries
|
|
gptkbp:route_of_administration
|
intramuscular injection
|
|
gptkbp:side_effect
|
fatigue
headache
muscle pain
fever
injection site reactions
rare allergic reactions
|
|
gptkbp:target_audience
|
adults
|
|
gptkbp:targets
|
gptkb:COVID-19
|
|
gptkbp:type
|
protein subunit vaccine
|
|
gptkbp:vaccine_development_start
|
gptkb:2020
|
|
gptkbp:vaccine_distribution_partners
|
gptkb:GAVI
gptkb:COVAX
gptkb:WHO
|
|
gptkbp:vaccine_updates
|
regularly published
|
|
gptkbp:whoapproval
|
yes
|
|
gptkbp:bfsParent
|
gptkb:Lonza_Group
|
|
gptkbp:bfsLayer
|
6
|